New research suggests the blockbuster weight-loss drugs may carry a hidden cost — one that could redefine how doctors weigh the risks and rewards of long-term use.
GLP-1 receptor agonists — the class of drugs reshaping conversations about obesity, diabetes, and even heart disease — may be carrying a side effect that has largely flown under the radar: a measurable increase in bone and joint disorders.
That is the finding emerging from new research set to be presented at the American Academy of Orthopaedic Surgeons’ annual meeting. The study, led by Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, examined more than five years of medical records for over 146,000 adults living with both obesity and Type 2 diabetes. What he found adds an important layer of complexity to a drug category that has been widely praised for its transformative potential.
The GLP-1 Numbers Behind the Concern
Among the GLP-1 users in the study, 4 percent developed osteoporosis — a condition in which bones become progressively weaker and more brittle — compared to 3 percent of those not on the medications. Meanwhile, 7.4 percent of GLP-1 users developed gout, a form of inflammatory arthritis caused by the buildup of uric acid crystals in the joints, most commonly in the big toe. That figure stood at 6.6 percent among non-users.
While the gap may appear modest in isolation, Horneff emphasized that the picture becomes more striking when looking further ahead. Within that same dataset, the risk of developing some form of bone mineral density loss was nearly doubled over a five-year period for those taking GLP-1 medications.
Why the Body May Be Paying a Price
Part of the explanation, according to Horneff, lies in how GLP-1 drugs work. These medications, which act on receptors in the brain to suppress appetite and increase feelings of fullness, naturally lead users to eat less — and in doing so, to absorb fewer of the vitamins and minerals that bones depend on to remain dense and healthy.
But Horneff has advanced a second theory that takes the conversation in a more unexpected direction. He draws a comparison to astronauts returning from extended missions in zero gravity — a population well-known in medical circles for experiencing significant bone density loss when their skeletons are freed from the burden of supporting their own weight.
The reasoning follows a similar logic: when a patient loses a significant amount of body weight, the skeleton — which has spent years adapting to carry that mass — suddenly faces far less mechanical demand. With less weight to bear, bones may begin to thin in ways that mirror what happens when gravity is removed from the equation entirely. The body, in essence, stops reinforcing what it no longer believes it needs.
Balancing Breakthroughs With Bone Health Risks
None of this is to suggest that GLP-1 drugs — which have demonstrated remarkable results in weight management, cardiovascular health, and blood sugar regulation — should be viewed with alarm. Horneff himself was careful to frame his findings within a broader context of the medications’ well-documented benefits.
Patients are clearly deriving enormous value from these drugs. The findings are not a reason to stop taking them. They are, however, a reason for both patients and clinicians to be more intentional — about monitoring bone density, ensuring adequate calcium and vitamin D intake, and incorporating weight-bearing exercise that can help counteract the skeletal changes that rapid weight loss may trigger.
As GLP-1 medications continue to expand their reach — with millions of prescriptions written annually and new indications under study — research like Horneff’s serves as an important reminder that the full picture of long-term use is still coming into focus. The drugs may be changing lives. But as the data accumulates, so too does the responsibility to understand exactly what those changes cost.
Source: People
